Oral Presentations
Parallel Session: HCV Direct Acting Antivirals
61 TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS ACHIEVES SVR12 OF 78% IN GT2/3 INTERFERON-INELIGIBLE, -INTOLERANT, OR -UNWILLING PATIENTS: RESULTS OF THE PHASE 3 POSITRON TRIAL

https://doi.org/10.1016/S0168-8278(13)60063-XGet rights and content

References (0)

Cited by (0)

View full text